医学
抗组胺药
非索非那定
药效学
安慰剂
药代动力学
皮肤病科
临床试验
随机对照试验
内科学
麻醉
药理学
替代医学
病理
作者
Pablo Rodríguez del Río,Fernando Rodríguez Fernández,Esther Asensio,Miguel Tortajada‐Girbés
出处
期刊:Immunotherapy
[Future Medicine]
日期:2022-01-01
卷期号:14 (1): 77-89
被引量:4
标识
DOI:10.2217/imt-2021-0251
摘要
Management guidelines for allergic rhinitis and urticaria recommend oral second-generation antihistamines as first-line treatment. The efficacy and safety of bilastine, the newest nonsedating second-generation antihistamine, are well established in adolescents/adults with these allergic conditions. The bilastine development program for pediatric use (2-<12 years) followed EMA-authorized processes. Pharmacokinetic/pharmacodynamic simulation and modeling and a pharmacokinetic study were conducted to identify and confirm the pediatric dose (10 mg/day). A Phase III, multicenter, double-blind, randomized, placebo-controlled, parallel-group study was performed to confirm the safety of bilastine 10 mg/day in children. In this article, evidence is reviewed for use of bilastine in children with allergic rhinoconjunctivitis or urticaria. Several cases are presented which demonstrate its role in routine clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI